/
Cardiovascular
Myocardial Infarction
74
Pipeline Programs↗
146
Active Trials↗
53
Companies Involved↗
Myocardial Infarction is a moderately active landscape with 74 programs across 53 companies. The most active players are Amgen, Novartis. 21 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical48
Phase 11
Phase 24
Phase 321
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
62 of 67 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 99% of 74 pipeline programs.
Analysis
Trial Status
538
clinical trials
Completed275 · 51%
Recruiting81 · 15%
Unknown status75 · 14%
Not yet recruiting35 · 7%
Active, not recruiting28 · 5%
Withdrawn21 · 4%
Other23 · 4%
Clinical Trials
Trial Activity
538 trials
Page 1 of 36
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)